Avalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed
Avalyn Pharma (AVLN) reported Q2 2026 results and said enrollment is complete for the global Phase 2b MIST trial of inhaled AP01 (pirfenidone) in progressive pulmonary fibrosis. The randomized, double-blind study enrolled 398 patients vs a 375 target, with 52-week safety and efficacy and topline data expected in H2 2027. Q2 R&D was $24.7M, net loss $28.9M, and cash $413.5M.
How this was made
The 30-second read
Why it matters
The key new information is the completion of Phase 2b MIST enrollment for AP01, including the final enrolled count and the company’s stated timeline for topline results. Financial results and cash runway into 2029 provide additional context for funding risk.
Market read
This is a trial-execution milestone plus a forward timeline update, which can support valuation via reduced operational risk but leaves efficacy/safety as the next major unknown.
What to watch
R&D and G&A expense run-rate increased materially, and the next decision point is still 2027 topline, leaving limited near-term fundamental information.
Background
Avalyn is a clinical-stage biopharma developing lung-targeted inhaled antifibrotics, including AP01 (pirfenidone inhaled) for progressive pulmonary fibrosis.
Ticker impact
Avalyn completed enrollment in its global Phase 2b MIST trial of AP01 (pirfenidone inhaled), enrolling 398 patients vs 375 target.
Near-term upside bias from reduced execution risk, but the main price catalyst remains topline data in 2H 2027.
The article provides a concrete milestone (enrollment completed, sample size) plus a specific future reporting window, which can re-rate probability of success and timing, though it is not a new efficacy/safety readout.
Market effects
Adds incremental momentum to inhaled antifibrotic development narratives, but does not introduce new competitive efficacy data.
No specific regional demand or regulatory signal beyond planned ERS Congress presentations.
Global Phase 2b enrollment completion supports international trial execution credibility, relevant for cross-region biotech sentiment.
Counterpoint
Enrollment completion does not reduce uncertainty about efficacy or safety; without interim data, the market may be over-discounting the milestone.
Key entities
- companyAvalyn Pharma Inc.
Clinical-stage biopharmaceutical developing inhaled antifibrotic therapies; subject of the update.
- programAP01
Inhaled formulation of pirfenidone being tested in the Phase 2b MIST trial for progressive pulmonary fibrosis.
- clinical_trialMIST trial
Global randomized, double-blind, placebo-controlled Phase 2b study; enrollment completed with 398 patients.
- programAP02
Inhaled formulation of nintedanib in the Phase 2 AURA trial for idiopathic pulmonary fibrosis.
- programAP03
Fixed-dose inhaled combination of pirfenidone and nintedanib; Phase 1 expected to start by end of 2026.
